REFERENCES
- Borchmann P, Hubel K, Schnell R, Engert A. Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997; 35: 80–3.
- Hollingshead LM, Faulds D. Idarubicin: a review of its pharmacodynamic and pharmacokinetic properties, and thera-peutic potential in the chemotherapy of cancer. Drugs 1991; 42: 690–719.
- Leoni F, Ciolli S, Giulliani G, et al. Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharma-cokinetic study and clinical results. Br J Haematol 1995; 90: 169–74.
- Reiffers J, Huguet F, Stoppa AM, et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996; 10: 389–95.
- Tamura K. A phase I study of idarubicin hydrochloride in patients with acute leukemia. Semin Hematol 1996; 33: 2–11.
- Villani F, Galimberti M, Comazzi R, Crippa F. Evaluation of cardiac toxicity of idarubicin (4-demethoxy-daunorubicin). Eur J Clin Oncol 1989; 25: 13–8.
- Wiernik PH, Banks PLC, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as introduction and consolida-tion therapy for previously untreated adult patients with acute myeloid Leukemia. Blood 1992; 79: 313–9.
- Toffoli G, Simone F, Gigante M, Boiocchi M. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant lovo cell lines. Biochem Pharmacol 1994; 48: 1871–81.
- Kuffel MJ, Ames MM. Comparative resistance of idaru-bicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells. Cancer Chemother Pharmacol 1995; 36: 223–6.
- Camaggi CM, Strocchi E, Carisi P, Marton' A, Tononi A, Guaraldi M, Strolin Benedetti M, Efthymiopoulos C, Pannuti F. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol 1992; 30: 307–16.
- Toffoli G, Corona G, Simone F, Gigante M, De Angeli S, Boiocchi M. Cellular pharmacology of idarubicinol in mul-tidrug-resistant lovo cell lines. Int J Cancer 1996; 67: 129–37.
- Toffoli G, Sorio R, Aita P, et al. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin Canc Res 2000; 6: 2279–87.
- Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 1993; 24: 275–88.
- Stewart DJ, Grewaal D, Green RM, et al. Bioavailability and pharmacology of oral idarubicin. Cancer Chemother Pharmacol 1991; 27: 308–14.
- Dodion P, Sanders C, Rombault W, et al. Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxy-daunorubicinol against human normal myeloid stem cells and human malignant cells in vitro. Eur J Cancer Clin Oncol 1987; 23: 1909–14.
- Nies AS, Spielberg SP. Pinciples of therapeutics. In: Goodman Gilman JG, Hardman LE, Limbird PB, Molinoff R, Ruddon W (eds.) The pharmacological basis of therapeutics. McGraw-Hill, New York, 1995: 46-62.
- Zanette L, Zucchetti, Freshi A, Erranti D, Tirelli U, D'Incalci M. Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. Cancer Chemother Pharmacol 1990; 25: 445–8.
- Kamen BA, Rubin E, Aisner J. High-time chemothera-py or high time for low dose? J Clin Oncol 2000; 18: 2935–7.
- Schleyer E, Kuhn S, Ruhrs H, et al. Oral idarubicin pharmacokinetics - correlation of trough level with idarubicin area under curve. Leukemia 2000; 10: 707–12.